![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, July 07, 2014 9:48:12 AM
Reason: Too risky and expensive to get a product like this through FDA approval, and fight lawsuits. If they hope to entrench into the US market, they will need a brand name and deep pockets to lean on. ISRG had the "revolutionary" card to play, because they were first. Cost compared to DaVinci counts, but not so much as you might think in large hospital environments that set the stage for new surgeons. Outcomes are the metric, and even DaVinci is not in the clear with proving its outcomes are better.
So far in looking at the few videos by Titan, no surgeon I have told about Titan has said "wow". That bothers me because a lot of posters here think this thing is automatically the second coming.
I am long on Titan with 10k shares, but I hope they've got a lot more that we haven't seen yet, if they think they are going to go it alone.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM